Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 5/20 | 0.64 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418615 | 0.89 | SERPINE1 (0.50) | SERPINE1ACMSDHDAC1HDAC2DEGS1 | |
| SCHEMBL422315 | 0.82 | SERPINE1 (0.81) | SERPINE1ACMSDHDAC1DEGS1HDAC3 | |
| SCHEMBL29838729 | 0.82 | SERPINE1 (0.81) | SERPINE1ACMSDHDAC1DEGS1HDAC3 | |
| SCHEMBL419193 | 0.78 | SERPINE1 (1.00) | SERPINE1DEGS1HDAC3HDAC8HDAC6 | |
| SCHEMBL416727 | 0.75 | SERPINE1 (0.70) | SERPINE1ACMSDHDAC1DEGS1HDAC3 | |
| SCHEMBL419124 | 0.75 | SERPINE1 (0.66) | SERPINE1HDAC1DEGS1HDAC3HDAC8 | |
| SCHEMBL27882359 | 0.74 | HDAC1 (0.44) | ACMSDHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL29838650 | 0.73 | SERPINE1 (0.66) | SERPINE1ACMSDHDAC1DEGS1HDAC3 | |
| SCHEMBL416992 | 0.73 | SERPINE1 (0.66) | SERPINE1ACMSDHDAC1DEGS1HDAC3 | |
| SCHEMBL419036 | 0.73 | SERPINE1 (1.00) | SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039276-A1 | INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE | Renascience Inc. (JP) | 2022-08-10 | — | — | EP | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2990057-B1 | PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT | RENASCIENCE CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885ACMSD 3080/4885HDAC1 457/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885ACMSD 4062/4885HDAC1 287/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885ACMSD 4062/4885HDAC1 287/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885ACMSD 2527/4885HDAC1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.